BRENT WILLARD: Open Payments
NPI 1336551084 · SAN BERNARDINO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$350 in 15 payments from 7 companies in 2025. Trend: 2023 $255 · 2024 $206 · 2025 $350
Food & beverage: $350
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 7 | $164 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Neurocrine BioSciences, Inc. | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
Products named: ARISTADA, INGREZZA, AUSTEDO XR, CAPLYTA, REXULTI, VIVITROL, ABILIFY ASIMTUFII, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
